Punta Arenas

Researchers are evaluating a new multi-component score called the Readiness for EXtubation score (REXs) to predict when ICU patients on invasive mechanical ventilation are ready for extubation. Extubation readiness is determined through clinical criteria including improvement in underlying conditions, hemodynamic stability, and adequate respiratory effort. The study addresses the challenge of safely removing patients from mechanical ventilation by improving prediction of extubation success, defined as not needing invasive support within 48 hours after tube removal. The study involves screening ICU patients on invasive mechanical ventilation daily to collect various clinical data including ventilation parameters, blood gases, respiratory muscle strength, cough ability, sedation levels, heart rate, hemoglobin, and nutrition status. These data will be anonymously recorded in an electronic case report form. The REXs score will be developed and analyzed based on these parameters to predict extubation readiness. The target enrollment is about 470 patients to account for a 10% dropout rate. Participants will be monitored throughout the weaning process with assessments such as spontaneous breathing trials, arterial blood gas measurements, ventilator settings, and sedation scores. The primary outcome is extubation failure within 48 hours after extubation. Statistical analyses will evaluate associations between clinical variables and extubation outcomes, and the REXs score's predictive ability will be examined. Data collection, monitoring, and safety evaluations will occur during patients' ICU stay until hospital discharge or death.

Gallstones are common in women and are a major risk factor for gallbladder cancer (GBC), a serious disease with limited treatment options. This research aims to improve how well we can predict the risk of GBC and detect it early by studying differences in geography, environment, lifestyle, ethnicity, gender, and molecular markers. The goal is to develop better prevention programs and improve understanding of how lifestyle and genetic factors contribute to GBC development. The study involves collecting epidemiological, clinical, and dietary information, along with samples of blood, saliva, urine, bile, feces, and gallbladder tissue. These samples will be used to identify and study new biomarkers for GBC, build a biorepository, develop a risk scoring system, and explore new treatment options. The study includes patients with gallbladder cancer or precancerous conditions and those with gallstones scheduled for gallbladder removal. Participants will provide various samples and data which researchers will use to measure the number of participants developing gallbladder cancer or dysplasia, either at the start or after examination of removed gallbladders. The project also supports training researchers and aims to help shape health policies. The study is observational and does not involve any experimental treatments, focusing instead on gathering data to improve prevention, diagnosis, and future treatments for GBC.

The Pompe Registry is a global, multicenter, international program that follows patients with Pompe disease over time. It is an observational and voluntary study designed to track the natural history and outcomes of Pompe disease in both treated and untreated patients. The registry aims to improve understanding of the disease's variability, progression, identification, and natural history, with the goal of guiding and assessing therapeutic interventions. It also supports the Pompe medical community in developing monitoring recommendations and reporting patient outcomes to optimize care. Additionally, the registry helps characterize the Pompe disease population and evaluates the long-term effectiveness of alglucosidase alfa. This study collects data retrospectively and prospectively from patients worldwide diagnosed with Pompe disease. It does not involve any specific interventions or treatments but gathers comprehensive clinical information over time. Data collection includes medical history, diagnosis details, treatment status, and other relevant health information to better understand the disease and patient experiences. Participants contribute data through regular updates that capture their disease progression and treatment outcomes. Researchers use this information to study how Pompe disease manifests and changes over time, with a maximum follow-up period of 30 years. The registry helps fulfill regulatory commitments, supports product development and reimbursement, and provides valuable information for research and patient care improvements.

Researchers are evaluating the effect of balcinrenone/dapagliflozin compared with dapagliflozin alone on cardiovascular death and heart failure events in patients with chronic heart failure and impaired kidney function who recently experienced a heart failure event. This is a Phase III, international, randomized, double-blind, parallel-group, active-controlled study involving approximately 700 sites in about 40 countries. Participants will be randomly assigned in a 1:1:1 ratio to receive one of three treatments once daily: a capsule of balcinrenone/dapagliflozin 15 mg/10 mg with a placebo tablet, a capsule of balcinrenone/dapagliflozin 40 mg/10 mg with a placebo tablet, or a dapagliflozin 10 mg tablet with a placebo capsule. The study is event-driven, with an estimated average duration of 22 months that includes a screening period, a 20-month blinded treatment phase, and a one-month follow-up on open-label dapagliflozin. During the study, participants will be monitored for the time to first occurrence of cardiovascular death, heart failure hospitalization, or heart failure events without hospitalization over approximately 38 months. Assessments include clinical evaluations, laboratory tests, and safety monitoring throughout the study and follow-up period to track treatment effects and patient outcomes.